Top

The Patient - Patient-Centered Outcomes Research

Published in:

Open Access 01-06-2017 | Original Research Article

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©

Authors: Terry A. Jacobson, Steven V. Edelman, Nina Galipeau, Alan L. Shields, Usha G. Mallya, Andrew Koren, Michael H. Davidson

Published in: The Patient - Patient-Centered Outcomes Research | Issue 3/2017

Abstract

Introduction

The National Lipid Association Statin Intolerance (SI) Panel recognized the need for better understanding of the patient SI experience.

Objective

The objective of this research was to develop a patient-reported outcome (PRO) questionnaire to assess a patient’s experience with SI.

Methods

Questionnaire development was informed via a series of research activities: literature review, concept elicitation, item generation, and content evaluation. Following the literature review and concept elicitation, a draft questionnaire was constructed and subsequently modified based on feedback from therapeutic area experts and patients via cognitive debriefing interviews.

Results

Muscle-related symptoms were the most commonly reported symptoms associated with SI in the literature review (35 of 41 articles reviewed [85%]) and in semi-structured interviews with experts (n = 5 [100%]) and patients (n = 17 of 20 [85.0%]). Physical and other impacts of SI symptoms on daily activities were also frequently reported. A 17-item draft questionnaire was created, and cognitive debriefing with experts (n = 5) and patients (n = 15) was conducted. Overall, the items, response options, and instructions were comprehensible and positively reviewed; minor changes resulted in the 15-item Statin Experience Assessment Questionnaire (SEAQ)©. Using a 30-day recall period, the SEAQ© assesses the severity and impact of six SI symptoms (muscle ache, muscle pain, muscle cramps, muscle weakness, tiredness, and joint pain) on an 11-point numeric scale. Statin discontinuation and likelihood of discontinuation due to symptoms are assessed and scored on a yes/no and five-point verbal response scale, respectively.

Conclusion

The SEAQ© is a novel content-valid PRO questionnaire that assesses patient SI experience and fosters dialogue about SI between patients and providers.

Available only for authorised users

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322. doi:10.1161/CIR.0000000000000152.CrossRefPubMed

Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151–67. doi:10.1016/j.cjca.2012.11.032.CrossRefPubMed

European Association for Cardiovascular Prevention & Rehabilitation. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818. doi:10.1093/eurheartj/ehr158.CrossRef

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9(2):129–69. doi:10.1016/j.jacl.2015.02.003.CrossRefPubMed

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. doi:10.1016/j.jacc.2013.11.002.

Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thromb. 2013;20(12):850–60. doi:10.5551/jat.19166.CrossRefPubMed

Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74. doi:10.1177/2047487314525531.CrossRefPubMed

McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94C. doi:10.1016/j.amjcard.2006.02.030.CrossRefPubMed

Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patient—the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14. doi:10.1007/s10557-005-5686-z.CrossRefPubMed

10.

Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23(8):1182–6. doi:10.1007/s11606-008-0636-7.CrossRefPubMedPubMedCentral

11.

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. doi:10.1016/j.jacl.2012.03.003.CrossRefPubMed

12.

El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44(6):877–81. doi:10.1002/mus.22205.CrossRefPubMed

13.

Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761–70. doi:10.1016/j.clinthera.2007.08.022.CrossRefPubMed

14.

Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. doi:10.1161/CIRCULATIONAHA.112.136101.CrossRefPubMed

15.

Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34. doi:10.7326/0003-4819-158-7-201304020-00004.CrossRefPubMedPubMedCentral

16.

Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36:S325–30. doi:10.2337/dcS13-2038.CrossRefPubMedPubMedCentral

17.

Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81. doi:10.1016/j.jacl.2014.03.002.CrossRefPubMed

18.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. doi:10.1093/eurheartj/ehv043.CrossRefPubMedPubMedCentral

19.

Sanchez RJ, Graham JH, Evans MA, Mallya UG, Panaccio MP, Steinhubl SR. Clinical and economic consequences of statin intolerance in the U.S.: Results from an integrated health system [abstract]. Circ Cardiovasc Qual Outcomes. 2015;8(Suppl 2):A146.

20.

Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes. 2011;4:155–66. doi:10.2147/DMSO.S11244.CrossRefPubMedPubMedCentral

21.

Peterson ED, Ho PM, Barton M, Beam C, Burgess LH, Casey DE Jr, et al. ACC/AHA/AACVPR/AAFP/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2014;64(20):2133–45. doi:10.1016/j.jacc.2014.09.003.CrossRefPubMedPubMedCentral

22.

Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59–82. doi:10.1177/1525822X05279903.CrossRef

23.

Lamoureux RE, Shields A, Stokes J, Yaworsky A, Galipeau N. How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies [abstract]. Value Health. 2015;18(3):A33. doi:10.1016/j.jval.2015.03.198.CrossRef

24.

Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1—eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77. doi:10.1016/j.jval.2011.06.014.CrossRefPubMed

25.

Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Value Health. 2009;12(8):1075–83. doi:10.1111/j.1524-4733.2009.00603.x.CrossRefPubMed

26.

Friese S. ATLAS ti 7 User Manual. Berlin: ATLASti Scientific Software Development GmbH; 2013.

27.

Abdulrazzaq HA, Sulaiman SAS. Prediction of renal impairment induced by statin therapy in cardiac outpatients. Int J Pharm Pharm Sci. 2012;4(Suppl 1):371–3.

28.

Abdulrazzaq HA, Sulaiman SAS. Neurological adverse drug reactions and statin therapy. Int J Pharm Pharm Sci. 2012;4:446–9.

29.

Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119(5):400–9. doi:10.1016/j.amjmed.2006.02.007.CrossRefPubMed

30.

Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007;100(3):554–5. doi:10.1016/j.amjcard.2007.03.059.CrossRefPubMed

31.

Baykal D. An update on statin safety with an emphasis on differences. LipidSpin. 2013;11:5–8.

32.

Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol. 2006;97(8A):6C–26C. doi:10.1016/j.amjcard.2005.12.006.CrossRefPubMed

33.

Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic. J Clin Pharm Ther. 2011;36(3):336–41. doi:10.1111/j.1365-2710.2011.01254.x.CrossRefPubMed

34.

Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541–53. doi:10.1592/phco.30.6.541.CrossRefPubMedPubMedCentral

35.

Chee YJ, Chan HHV, Tan NC. Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review. Singapore Med J. 2014;55(8):416–21. doi:10.11622/smedj.2014099.CrossRef

36.

Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014;37(3):131–9. doi:10.1002/clc.22248.CrossRefPubMed

37.

Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int J Cardiol. 2011;152(1):56–60. doi:10.1016/j.ijcard.2010.07.006.CrossRefPubMed

38.

Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291(6):C1208–12. doi:10.1152/ajpcell.00226.2006.CrossRefPubMed

39.

Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab. 2010;95(5):2015–22. doi:10.1210/jc.2009-2689.CrossRefPubMed

40.

Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800–11. doi:10.1592/phco.29.7.800.CrossRefPubMed

41.

Fitzgerald K, Redmond E, Harbor C. Statin-induced myopathy. Glob Adv Health Med. 2012;1(2):32–6. doi:10.7453/gahmj.2012.1.2.008.CrossRefPubMedPubMedCentral

42.

Friedrich DA. Vitamin D deficiency and statin intolerance. LipidSpin. 2013;11:21–2.

43.

Fujimoto M, Hosomi K, Takada M. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS. Int J Clin Pharmacol Ther. 2014;52(4):259–66. doi:10.5414/CP202033.CrossRefPubMed

44.

Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy [editorial]. Ann Intern Med. 2013;158(7):562–3. doi:10.7326/0003-4819-158-7-201304020-00010.CrossRefPubMed

45.

Harris LJ, Thapa R, Brown M, Pabbathi S, Childress RD, Heimberg M, et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J Clin Lipidol. 2011;5(4):299–307. doi:10.1016/j.jacl.2011.05.005.CrossRefPubMed

46.

Harrison TN, Derose SF, Cheetham TC, Chiu V, Vansomphone SS, Green K, et al. Primary nonadherence to statin therapy: patients’ perceptions. Am J Manag Care. 2013;19(4):e133–9.PubMed

47.

Holbrook A, Wright M, Sung M, Ribic C, Baker S. Statin-associated rhabdomyolysis: is there a dose-response relationship? Can J Cardiol. 2011;27(2):146–51. doi:10.1016/j.cjca.2010.12.024.CrossRefPubMed

48.

Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med. 2014;4(2):147–62. doi:10.3390/jpm4020147.CrossRefPubMedPubMedCentral

49.

Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. doi:10.1007/s11883-012-0291-7.CrossRefPubMedPubMedCentral

50.

Mareedu RK, Modhia FM, Kanin EI, Linneman JG, Kitchner T, McCarty CA, et al. Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol. 2009;12(2):88–94. doi:10.1111/j.1751-7141.2009.00028.x.CrossRefPubMedPubMedCentral

51.

Matteucci E, Giampietro O. Statin intolerance: why and what to do—with a focus on diabetic people. Curr Med Chem. 2013;20(11):1397–408. doi:10.2174/0929867311320110004.CrossRefPubMed

52.

Nair RK, Karadi RL, Kirpatrick ES. Managing patients with ‘statin intolerance’: a retrospective study. Br J Cardiol. 2008;15(3):158–60.

53.

Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–72.CrossRefPubMed

54.

Roberto G, Biagi C, Montanaro N, Koci A, Moretti U, Motola D. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol. 2012;68(6):1007–11. doi:10.1007/s00228-012-1218-5.CrossRefPubMed

55.

Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2013;23(9):871–5. doi:10.1016/j.numecd.2012.04.012.CrossRefPubMed

56.

Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One. 2011;6(12):e28124. doi:10.1371/journal.pone.0028124.CrossRefPubMedPubMedCentral

57.

Shannon JA, John SM, Parihar HS, Allen SN, Ferrara JJ. A clinical review of statin-associated myopathy. J Pharm Technol. 2013;29(5):219–30. doi:10.1177/8755122513500915.CrossRef

58.

Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253–60. doi:10.1016/j.clinthera.2007.02.008.CrossRefPubMed

59.

Tompkins R, Schwartzbard A, Gianos E, Fisher E, Weintraub H. A current approach to statin intolerance. Clin Pharmacol Ther. 2014;96(1):74–80. doi:10.1038/clpt.2014.84.CrossRefPubMed

60.

Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, et al. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2008;31(12):1115–23. doi:10.2165/0002018-200831120-00007.CrossRefPubMed

61.

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83. doi:10.1016/j.jacl.2013.03.001.CrossRefPubMed

62.

Welding JM, Ragheb B. Evidence-based approach to the use of CoQ10 to deal with statin intolerance. LipidSpin. 2013;11(4):13–4.

63.

Zysek V, Spoon J, Kopecky S. Mayo Clinic: management of patients with statin intolerance. Clin Lipidol. 2013;8(5):541–9. doi:10.2217/clp.13.54.CrossRef

64.

Zetia [package insert]. Whitehouse Station: Merck and Co; 2013.

65.

Lipitor [package insert]. New York: Pfizer; 2015.

66.

Vytorin [package insert]. Whitehouse Station: Merck and Co; 2015.

67.

Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59–65. doi:10.1001/jama.1995.03520250075037.CrossRefPubMed

68.

US Department of Health and Human Services, Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed 19 May 2016.

69.

Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert Panel: An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71. doi:10.1016/j.jacl.2014.03.004.CrossRefPubMed

70.

American College of Cardiology. Statin intolerance [mobile application]. http://www.acc.org/StatinIntoleranceApp. Accessed 19 May 2016.

71.

Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18(9):1263–78. doi:10.1007/s11136-009-9540-9.CrossRefPubMed

72.

Burke LB, Kennedy DL, Miskala PH, Papadopoulos EJ, Trentacosti AM. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther. 2008;84(2):281–3. doi:10.1038/clpt.2008.128.CrossRefPubMed

73.

Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269–81. doi:10.1586/erp.10.30.CrossRefPubMed

74.

Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al. PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res. 2010;19(8):1087–96. doi:10.1007/s11136-010-9677-6.CrossRefPubMedPubMedCentral

75.

Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23. doi:10.5114/aoms.2015.49807.CrossRefPubMedPubMedCentral

76.

Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19. doi:10.1016/j.pain.2004.09.012.CrossRefPubMed

Authors: Terry A. Jacobson
Steven V. Edelman
Nina Galipeau
Alan L. Shields
Usha G. Mallya
Andrew Koren
Michael H. Davidson
Publication date: 01-06-2017
Publisher: Springer International Publishing
Published in: The Patient - Patient-Centered Outcomes Research / Issue 3/2017
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI: https://doi.org/10.1007/s40271-016-0211-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay

The Voice of the Patient Methodology: A Novel Mixed-Methods Approach to Identifying Treatment Goals for Men with Prostate Cancer

Giving Patients’ Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public–Private Project

Examination of the Applicability of the Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire to Patients with Hand Injuries and Diseases Using Rasch Analysis

Development of a Patient-Reported Palliative Care-Specific Health Classification System: The POS-E

What’s Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials